Ind-Swift Company Description
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India.
The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names.
It also offers medicines for various therapeutic comprising gynaecology, pediatrics, dermatology, and other generic medicines under the Anin, Suprox, Cozy, Distone, and Oliade name.
In addition, the company provides antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-depressant, anti-allergic, anti- infective, neurology, and oncology.
Ind-Swift Limited provides Ayurvedic products, as well as contract research and manufacturing services.
The company exports its products, as well as licenses its products to Europe, Australia, Canada, South Africa, and Russia.
Swift Limited was founded in 1983 and is based in Chandigarh, India.
Country | India |
Founded | 1983 |
Industry | Pharmaceutical Preparations |
Employees | 1,054 |
CEO | Gopal Munjal |
Contact Details
Address: 781, Industrial Area Chandigarh, Chandigarh 160002 India | |
Phone | 91 17 2263 8781 |
Website | indswiftltd.com |
Stock Details
Ticker Symbol | 524652 |
Exchange | Bombay Stock Exchange |
Fiscal Year | April - March |
Reporting Currency | INR |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Gopal Munjal | Chief Executive Officer |
Arun Seth | Chief Financial Officer |
Ravi Bhardwaj | Chief Operating Officer |